Methylprednisolut (Methylprednisolone Hydrogen Succinate)

Methylprednisolut is a systemic glucocorticoid used to manage inflammatory and immune‑mediated conditions.

• Acute exacerbations of multiple sclerosis: reduce inflammation and improve neurological function
• Severe allergic reactions (e.g., anaphylaxis): rapidly suppress immune response and alleviate symptoms
• Asthma exacerbations: decrease airway inflammation and improve breathing
• Rheumatoid arthritis flares: lower joint inflammation and pain
• Organ transplant rejection prophylaxis: prevent immune‑mediated graft damage

• Methylprednisolone binds to intracellular glucocorticoid receptors, forming a complex that translocates to the nucleus and modulates gene transcription. This interaction down‑regulates pro‑inflammatory cytokines, adhesion molecules, and enzymes such as phospholipase A2, while up‑regulating anti‑inflammatory proteins, resulting in reduced inflammation and immunosuppression.

Methylprednisolut may cause a range of adverse reactions.

Common Side Effects

• Increased blood glucose levels
• Insomnia or sleep disturbances
• Mood changes, including euphoria or irritability
• Increased appetite and weight gain
• Fluid retention leading to peripheral edema
• Elevated blood pressure

Serious or Rare Side Effects

• Adrenal insufficiency on abrupt discontinuation
• Severe infections, including opportunistic pathogens
• Osteonecrosis of the femoral head
• Gastrointestinal bleeding or ulceration
• Psychosis or severe mood disorders
• Anaphylactic or severe hypersensitivity reactions

Before initiating therapy, clinicians should consider several safety measures.

• Assess infection risk: evaluate for active infections prior to use
• Monitor blood glucose: patients with diabetes may require dose adjustments
• Screen for osteoporosis: long‑term therapy can reduce bone density
• Observe for psychiatric symptoms: mood swings or psychosis may occur
• Avoid abrupt discontinuation: taper dose to prevent adrenal insufficiency
• Store at ambient temperature: keep in original container, protect from moisture and light

Methylprednisolut can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid)

• Potent CYP3A4 inhibitors (e.g., ketoconazole): may increase systemic exposure
• Live vaccines: immunosuppression can reduce efficacy and increase risk
• Anticoagulants (e.g., warfarin): enhanced anticoagulant effect
• NSAIDs: increased risk of gastrointestinal ulceration
• Diabetes medications: may require dose adjustment due to hyperglycemia

Moderate Interactions (Monitor Closely)

• ACE inhibitors or ARBs: may potentiate sodium retention and hypertension
• Diuretics: may exacerbate electrolyte disturbances
• Antiretrovirals (e.g., protease inhibitors): may alter steroid metabolism